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1. Introduction 
Sacral neuromodulation (SNM) is an effective and increasingly used therapeutic option for 
refractory urge incontinence, chronic urinary retention and symptoms of urgency-frequency. 
The potential for neuromodulation has also been shown in patients with interstitial cystitis and 
neurogenic urge incontinence secondary to refractory detrusor hyperreflexia. With the 
increasing number of patients, obvious concerns and challenges raised. Young female patients  
who desire to conceive showed concerns pertaining to neuromodulation in pregnancy 
including possible teratogenic effect, symptom management  during pregnancy & the effect of  
mode of delivery on the Sacral electrode. Another concern is the need for MRI follow up in 
neurogenic patients. Post operative troubleshooting raises another challenge in patient 
management. In our chapter, we will discuss these challenges in details. 
2. Historical overview of neurostimulation 
Knowledge of the neurological associations among spinal marrow, nerves, and the urinary 
bladder arose after the middle of the nineteenth century. In 1863 Giannuzzi stimulated the 
spinal cord in dogs and concluded that the hypogastric and pelvic nerves are involved in 
regulation of the bladder (Giannuzzi, 1863).The first attempt at bladder stimulation occurred 
in 1878, when Saxtorph treated patients with urinary retention by way of intravesical 
electrical stimulation (Madersbacher, 1999) After experimentations with various methods of 
stimulating the bladder such as the transurethral approach, direct detrusor stimulation 
(Boyce et al, 1964), pelvic nerve stimulation (Dees JE, 1965), pelvic floor stimulation 
(Caldwell KP, 1963), and spinal cord stimulation (Nashold et al, 1971) were carried out. 
Based on the work of Tanagho and Schmidt it was demonstrated that stimulation of sacral 
root S3 generally induces detrusor and sphincter action (Heine et al, 1977) (Schmidt et al, 
1979) (Tanagho et al, 1982) (Tanagho, 1988).In 1988, Schmidt described the three stages of 
electrode placement (Schmidt, 1988). In 1988, a neuroprosthesis was first used for treatment 
of pelvic pain, and discomfort improved over 50% in 49% of patients (Schmidt, 1988). In 
1990, Tanagho presented the results of Neurostimulation for incontinence, 70% of 31 
patients with urge incontinence obtained subjective improvement of 50% or more, as did 
40% of 25 patients with post prostatectomy incontinence (Tanagho, 1990). Two years latter, 
Tanagho published the results of neuromodulation in 27 children: five of seven children 
with meningomyelocele gained continence, as did four of six patients with voiding 
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dysfunction and one of two patients with neonatal hypoxia (Tanagho, 1992). In 1998, Shaker 
and Hassouna evaluated the efficacy and safety of sacral root neuromodulation. They 
concluded that, for non obstructive urinary retention, sacral root neuromodulation is an 
appealing, efficacious treatment. Implantation is relatively simple and carries a low 
complication rate (Shaker & Hassouna, 1998).Finally, in October 1997, after two decades of 
experimentation with various approaches to sacral root stimulation, Sacral 
Neurostimulation (SNS)  was approved by the Food and Drug Administration (FDA) for the 
treatment of Urge incontinence  (UI) and Urgency –frequency syndrome (U/F). In 1999, it 
was approved for the treatment of non-obstructive urinary retention (NOUR). Since the 
approval, a number of technical advances has been made. The introduction of tined lead had 
made a dramatic change in surgical approach. Spinelli et al reported that the success rate of 
this technique in selective patients for the permanent implant is significantly higher (70%) 
than what is reported in the literature (50%). Outcomes of the implanted patients confirmed 
better patient selection with minimal complication. This technique allows the possibility of 
more accurate patient selection by using the definitive lead for longer test period before 
proceeding with the neurostimulator (IPG) implant ( Spinelli et al ,2003) . 
3. How does it work? 
The Exact Mechanism of action in not well understood. A number of theories have been 
proposed to explain the effect of electrical neuromodulation which can be summarized as: 
somatic afferent inhibition of sensory processing in the spinal cord. Regardless of whether 
the lower urinary tract dysfunction involves storage versus emptying abnormalities, the 
pudendal afferent signaling serves as a common crossroads in the neurologic wiring of the 
system. Not only can pudendal afferent input turn on voiding reflexes by suppressing the 
guarding reflex pathways, pudendal  afferent input to the sacral spinal cord also can turn off 
supraspinally mediated hyperactive voiding by blocking ascending sensory pathway inputs. 
(Kruse and Groat, 1993), (Thon et al, 1991), (Vadusek et al, 1986), (Groat et al, 1997), (Kruse 
et al, 1990), (Groat and Theobald, 1976) 
Other possible mechanisms of sacral nerve stimulation include: 
 Inhibits postganglionic neurons directly  
 May inhibit primary afferents presynaptically  
 Inhibits spinal tract neurons involved in the micturation reflex  
 Inhibits interneurons involved in spinal segmental reflexes  
 May suppress indirectly guarding reflexes by turning off bladder afferent input to 
internal sphincter  sympathetic or external urethral sphincter interneurons  
 Postganglionic stimulation can activate postganglionic neurons directly and induce 
bladder activity ( induce voiding), but at the same time can turn off bladder-to- bladder 
reflex by inhibiting afferent- interneuronal transmission. (Wendy and Michael, 2005) 
4. Indications for sacral nerve stimulation therapy 
The US Food and Drug Administration (FDA) approved Sacral neuromodulation (SNM) for 
three main conditions: intractable urge incontinence 1n 1997, and for urgency- frequency 
and non obstructive urinary retention in 1999 (Shaker & Hassouna, 1998).Latter, the labeling 
was changed to include “overactive bladder” as an appropriate diagnostic category (Abrams 
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et al, 2009). Patients in this group are considered candidates for SNS if they have chronic 
symptoms, refractory to medical therapy. (Apostolicism, 2011) (Knupfer, 2011)The 
Urodynamics study may or may not demonstrate uninhibited bladder contractions. Their 
symptoms include urinary urgency-frequency and urge incontinence (Al-Shaiji et al, 2011) 
(Abrams et al, 2003) (Siegel et al, 2000). Since its inception, widespread use for approved 
conditions has led to incidental improvements in other areas. Research is ongoing to channel 
the potential of neuromodulation into other applications. 
4.1 Neurogenic disorders 
Patients who have defined neurologic abnormalities such as multiple sclerosis (MS) or 
partial cord injury also may benefit from SNS, but studies in this population of patients have 
been few (Bosch and Groen, 1996)(Hassouna et al,2000). In spinal cord injured patients, 
detrusor hyperreflexia develops after spinal shock period resolves. Vastenholt reported 
(Vastenholt et al, 2003) a series of 37 patients with spinal cord injury who underwent 
implantation of sacral anterior root stimulation. He reported his 7 year follow-up of the 
group in which 87% continued using the implant for micturation control, 60% used it for 
benefits with respect to defecation. Of the 32 male patients, 65% were able to achieve a 
stimulator- induced erection. (Everaert etal, 1997) reported  the urodynamic changes in 27 
neuromodulation implanted patients with  spastic pelvic floor syndrome, bladder neck 
dysfunction, sphincter hypertonia, sphincter dysfunction, detroser overdistenstion and 
hypercontractile detroser. 
Other demyelinating disease as Guillain-Barre syndrome with voiding dysfunction has been 
reported to respond to sacral neuromodulation therapy (Wosnitzer et al, 2009). A study on 
incomplete spinal cord injured patients suffering from lower urinary tract symptoms 
showed that SNM is effective (Lombardi and Del, 2009). Chaabane et al reported a mean 
follow up of 4.3+/- 3.7 years, SNM is still effective in neurogenic bladder dysfunction 
group, and failures depend on the progression of the underlying neurological disease which 
usually are reported in the first year of follow up (Chaabane et al, 2001).  
4.2 Interstitial cystitis (IC) and pelvic pain 
IC per se is not an FDA approved indication for SNM; these patients have a set of symptoms 
of frequency, urgency and pelvic pain which in combination considered as characteristic of 
IC. A lot of studies showed patient symptoms relieve with SNM (Lukban et al, 2002) 
(Everaert et al, 2001) improved patient quality of life & narcotic requirements in refractory 
IC (Siegel et al, 2001) (Comiter, 2003).Peters reported total of 18 out of 21 interstitial cystitis 
patients who used chronic narcotics before Interstim, with the remaining three using non-
narcotic analgesics. The mean narcotic use dropped from 81.6 mg/day Morphine Dose 
Equivalent (before implantation) that decreased afterward to 52.0mg/day (36%, P=0.015). 
Four of 18 patients ceased using all narcotics after permanent Interstim implantation (Peters, 
2003). Ghazwani et al reported long term follow up of 21 female patients with painful 
bladder syndrome in which 52% showed response to PNE and proceeded for permanent 
IPG implantation. They had a significant improvement in bladder pain and voiding 
parameters at 1- year follow-up which was maintained at 5 years, with improvement in 
urgency & average voided volume. (Ghazwani et al, 2011). Gajewski and Al-Zahrani 
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recommended SNM in these patients before any major invasive surgical interventions if the 
conservative measures have failed (Gajewski and Al-Zahrani, 2010). 
4.3 Chronic genitourinary pain 
SNM has been used to control a variety of forms of genitourinary pain. Chronic non 
bacterial prostatitis & chronic epididymo-orchalgia are a common challenge that had hope 
with SNM. Feler et al reported a 75% improvement in a 44y male diagnosed with chronic 
epididymitis and chronic non bacterial prostatitis (Feler et al, 2003).Vulvodynia consists of 
chronic vulvar discomfort including itching, burning and dyspareunia. Feler et al reported a 
71y female who suffered of Vulvodynia for 9 years in which  sacral neuromodulation 
provided excellent pain relief. (Feler et al, 2003). 
4.4 Sexual function 
There are few reported cases claiming improved sexual function in both male & females. 
Lombardi et al reported sacral neuromodulation for lower urinary tract function in male 
patients which showed impact on their erectile function. Total of 22 patients had their IEF-5 
score shifted from 14.6 to 22.2 (Lombardi et al, 2008). In females, papers reported 
improvement in sexual function index of arousal and lubrication in voiding dysfunction 
female group (Lombardi et al, 2008). Pauls et al reported total female sexual function index 
improvement (p=0.002), and significant improvement domains of desire (p=0.004) and 
lubrication (p=0.005) in voiding dysfunction group (Pauls et al, 2006).However, all these 
reported papers were reported in voiding dysfunction group. No studies were constructed 
yet on any pure sexual dysfunction cases. Signorello et al claimed that the improvement in 
quality of sexual function in female patients with overactive bladder correlates with 
improvement in urinary symptoms (Signorello et al, 2011). In unpublished data from our 
center, female sexual function overall indices improved in voiding dysfunction female 
group P=0.028 (CI-23.14- -1.62), the parameters of satisfaction=0.037 (CI -4.9- -0.0177) & 
lubrication P=0.018 (CI -6.082 - -0.687) showed significant improvement in comparison to 
the other parameters (Banakhar et al, 2011) 
4.5 Children 
Similar to adults, children are faced with various degrees of lower urinary tract dysfunction 
that often deteriorate upper tract function. Usual treatment modality of intermittent 
catheterization & Anticholinergics are not uniformly successful and major reconstructive 
procedures are needed. Humphreys et al reported SNM in 16 children with refractory 
voiding dysfunction with mean age of 11 years. His study group showed 75% improved or 
resolved urinary incontinence, 83% improved their nocturnal enuresis, urinary retention 
improved in 73% of patients (Humphreys et al, 2004) 
4.6 Non urologic indications 
Angina pectoris (Van at al,2011), chronic migraine ( Magis and Schoenen, 2011), fecal 
incontinence ( Pascuall et al, 2011). The overall published results for SNM include all 
etiologies of fecal incontinence. Melenhorst et al reported 132 patients who had temporary 
stimulation. 100 were implanted (75%), the mean age was 75 years (26 -75 years) and the 
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mean follow up was 25 months (2-63 months), the mean number of incontinence episodes 
decreased from 31 to 4.8 (P<0.0001) as documented in a bowel diary (Melenhorst et al,2007). 
SNM is also indicated for constipation ( Van et al, 2011) .Masin et all reported results in 34 
patients with chronic idiopathic constipation with a median follow-up of 12 months93-48). 
Cleveland Clinic Constipation score decreased significantly from (mean +/- SEM )14 +/- 8.3 
to 7.5 +/- 4.9 (Masin et al, 2005) Other indications include deep brain stimulation for 
Parkinson’s (Hilker, 2010) . 
5. Contraindications 
SNM is contraindicated in patients with anatomical bony abnormalities of the sacrum, in 
which transforaminal access may be difficult or impossible. Patients with mental incapacity 
or psychiatric illnesses rendering them incapable of operating the device Patients who have 
undergone an unsuccessful SNS Trial (test stimulation). Others include coagulation 
disorders and local acute sacrum infection. SNM appears to be safe in the presence of a 
cardiac pacemaker without cardioversion/ defibrillation technology (Wallace et al, 2007) 
(Roth, 2010). Some conditions are considered challenging as MRI & pregnancy; however, 
more details are discussed upcoming in the chapter.  
6. Surgical technique  
After complete clinical evaluation by history, examination & Urodynamics assessment, all 
patients need to fill up a voiding diary for minimum of 3 days (baseline), which will assess 
the number of voids, the voided volumes, the degree of urgency and in patients who 
experience inefficient voiding or retention, the amount voided versus catheterized volumes 
per 24 hours and the patient’s sense of completeness of evacuation. Associated symptoms 
such as pelvic pain and bowel symptoms are also assessed. Latter, this diary will be used to 
assess the patient objective response to the test stimulation trial. Patients are counseled for 
the option of sacral neuromodulation and procedure risk and benefits are discussed with the 
patient. The first crucial step in determining if the patient is a good candidate for definite 
implant is a test stimulation trial. Test stimulation can be either percutaneous nerve 
evaluation (PNE) also called one- stage implant, or two staged implant in which the first 
step in two staged implant is the test trial. 
6.1 One – Stage implant 
Patients will undergo stimulation test trial named percutaneous nerve evaluation (PNE), 
which will determine if the patient is a candidate for permanent SNM. PNE is done as an 
outpatient procedure. It involves placement of a thin insulated wire into the third sacral 
foramen. Usually fluoroscopy is needed to localize the foramen during the PNE insertion. In 
our center, we perform it without any fluoroscopy, rather than that, we depend on the 
landmarks & patient sensory and motor response for localization table 1. After describing 
the procedure for the patient, marking of the boney landmarks are done while patient is in 
the prone position. The greater sciatic notch is palpated & marked bilaterally. The level of 
the notch marks the Y axis. The Medline is marked; one fingerbreadth laterally on each side 
marks the X axis .The meeting point of the Y & X axis resembles the third sacral foramen see 
figure 1. After cleaning & draping, local anesthesia is used for the skin & subcutaneous 
www.intechopen.com
 
Topics in Neuromodulation Treatment 
 
40
tissue. In our center, we use 1% plain Lidocaine, for both sides. Usually 10 cc will be enough 
but sometimes additional 10cc will be needed in some patients, however, the maximum total 
injected Lidocaine is 20 cc of 1% to avoid side effects. 
 
The procedure is done bilaterally, and the side giving better response will be chosen for wire 
insertion .Using the foramen needle, Long foramen needle is usually needed in obese 
patients, the third sacral canal is cannulated at the marked area. During insertion an angle of 
60 degree should be maintained to access the canal. The sacral bone will be felt first; with 
minimal movement the canal can be cannulated. Then, the patient response is assessed by 
intermittent stimulation with external pulse generator (EPG). The target response of the 
thirds sacral foramen includes bellows contraction of the pelvic floor (e.g., rectum, vagina, 
scrotum and perineum) and planter flexion of the great toe, to some extent. S2 placement 
will result into planter flexion of the entire foot with lateral rotation, whereas S4 will reveal 
no lower extremity movement despite bellows response. Once the appropriate side and 
position is selected, the temporary unipolar lead is inserted through the needle and then 
connected to an external pulse generator and fixed with tape to the skin. At the end of the 
procedure the patient is given a voiding diary to fill up while the wire is in to assess her/his 
response for the stimulation. Patient is given instructions on how to manage the temporary 
lead during the test period to avoid any inadvertent migration or misuse. After a trial period 
of 3-5 days the patient will be assessed in the clinic for subjective and or, objective 
improvement by comparing the pre and post voiding diaries. If the patient developed 50% 
or more improvement (Subjectively or / and objectively), she/he will be considered as a 
candidate for permanent SNM implantation & removal of the temporary lead is done in the 
clinic. A baseline Sacrao-Coxygeal AP-Lateral X-rays are obtained to document lead 
position. If the patient claimed no benefit we question if they had intact sensation of the 
vibration at the target area, if not, a sacrao-coxygeal X-rays should be taken to rule out lead 
migration which is usually the cause of the false negative results. The maximum duration of 
this test is limited to 14 days to avoid bacterial contamination (Pannek et al, 2005). Antibiotic 
prophylaxis is not needed. 
Limitations of this approach include lead migration, and potential discrepancy in clinical 
response with the permanent quadripolar lead implantation. Short term test stimulation 
period as well as lead migration probably explains the relatively low success rate of PNE, 
estimated at around 50% (Peter et.al, 2003)(Borawaski et.al , 2007).According to Everaert 
et.al false- positive PNE compose 33% of cases in home  patients who have a beneficial test 
stimulation with a temporary lead do not continue to have a successful outcome after  the 
permanent lead implantation (Everaert et al ,2004) . In our center, we adapted an algorithm 
Tips 
*Be sure not to inject local anesthetic into the foramen, which will mask the desired 
response. To do so, we insert the needle until we hit bone before injecting which helps 
confirming that we are not passing through the halo of the foramen. 
*If the needle is inserted at the sciatic nerve, it would elect S3 stimulation response, to be 
sure that the needle is in the canal, use a second foramen needle and insert it just lateral 
to your target needle. If it hits bone, this confirms that your target needle is in the canal, 
but if not it means most probable you are not. 
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to minimize the false negative cases that can gain benefit from SNM but their test trials were 
negative see figure 2.  
 
Nerve root Motor response Sensory response 
S2 Anal sphincter contraction (A-P pinching 
of perineum/ coccyx), leg/heel rotation, 
planter flexion of foot, calf contraction. 
Sensory alteration of the base 
of penis or vagina. 
S3 Bellows (inwards contractions), plantar 
flexion of great toe. 
Rectal sensation, extending 
into scrotum or labia. 
S4 Bellows Rectal sensation only 
Table 1. Sacral roots,   motor and sensory response (Bullock and Siegel, 2010). 
6.2 Two – Stage implant 
If the patient is not a candidate for office-based test stimulation (e.g. obese, difficult anatomy, 
previous sacral surgery or unable to tolerate the procedure under local anesthesia) or did not 
respond to the in- office test, test stimulation may be performed in the operating room. 
Furthermore, the immediate implantation of a permanent lead aims to avoid lead migration 
and allows prolonged patient screening. (Kessler et.al. 2005)(Kessler et al, 2007). The procedure 
involves using the quadripolar leads which fix the lead into the foramen & avoid migration.  
The test response can be performed using intravenous sedation, local anesthesia or general 
anesthesia. In case of general anesthesia, the anesthetist is reminded to avoid any long- acting 
muscle relaxants which may impair sacral nerve stimulation or visualize their motor response. 
Note that the upper body nerves recover earlier than the sacral nerve, the anesthetist may 
claim recovery of the muscle relaxant in the absence of sacral response may imply delayed 
recovery and the surgeon may need to wait more time (about 10 minutes) to have a response. 
Fluoroscopy C- arm is used to facilitate placement of the quadripolar permanent lead. Once it 
is inserted into the foramen, using the foramen needle, followed by guide wire & foramen 
dilator, it is tested by bipolar stimulation(by EPG, PW210, Rate 14, Amplitude 10 volts) in all 4 
positions 0,1,2,3, for response. After which, the dilator sheath is withdrawn under fluoroscopic 
guidance figure 3. Fluoroscopy views are important and taken as baseline pictures to locate the 
S3 foramen in correlation with the greater sciatic notch and the skin marking which we made. 
Then during the lead insertion to confirm being in proper position & the last electrode is at the 
lower surface level of the sacral foramen. Finally, the dilator sheath is removed under 
continuous fluoroscopy to avoid electrode movement from its proper position ,and the last 
picture of the position will be considered as a baseline for future  patient fellow-up if 
developed any complications figure 4.The lead is then tunneled deeply through the 
subcutaneous fat to the right or left buttock depending on the patient dominant hand side 
where the permanent implantable pulse generator (IPG) will be placed in the second stage if 
the patient is considered as a candidate. The lead is attached to the temporary connector and 
then tunneled through the subcutaneous fat to an alternative exit site. This is particularly an 
important step because if the patient developed superficial skin infection, then the alternative 
exit site would help prevent the infection from spreading to the lead and future permanent 
IPG location (Kohli and Patterson, 2009). Finally, the lead is connected to an external pulse 
generator and taped to the skin surface. A test period of 14 days is used to determine which 
patient meets the criteria to have the permanent IPG implanted. At the end of the test period 
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the patient returns to the OR for either removal of the lead or implantation of the IPG, 
depending on the subjective and/ or objective responses, Figure 4D. 
 
Fig. 1. Landmarks for S3. The curved line on each side resembles the greater sciatic notch 
which level corresponds for the Y axis, while one fingerbreadth from the marked midline is 
the X axis. S3 foramen is the joining point between the Y and X axis. 
 
6.2.1 PNE versus staged testing 
The PNE is a simple, safe, inexpensive, office- based procedure which is carried out under 
local anesthesia .A prospective randomized study showed that the two stage implant 
technique of SNM has a higher success rate compared to the one- stage method despite prior 
positive PNE in both short & long term (Everaet et al, 2004). Another important study by 
Borawaski et al reported significant positive results in the two stages procedures who 
proceeded with IPG implantation more that the PNE group in a randomized study (88% 
compared to 46%)( Borawaski et al, 2007).Other studies reported that the sensory response 
assessment at the time of implantation reduced the reoperation rate from 43% to 0% (Peters 
et al,2003) .The cost for the test protocol with the tined leads ( two- stage procedure) are 
Tips 
If no response can be demonstrated by the stimulation check the connection between the 
hook & the EPG, if it was well connected, check the battery of the EPG which can be 
expired. If all are working properly most probably the nerves are still under the effect of 
the muscle relaxant. Ask the anesthetist to reverse the effect of muscle relaxant if feasible 
& wait for the nerve to recover. Notice that the upper body nerves recover faster than 
the sacral nerves. 
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much higher compared to the PNE . Currently, the use of either one of the two screening 
options is arbitrary. In our center, one –stage procedure is the trend unless the two stage is 
indicated with difficult PNE (technical, anatomical, not cooperative patient).In our hands, 
most of the PNE has high success rate in comparison to two- stage procedure see table 2.  
6.2.2 Unilateral versus bilateral test stimulation 
Unilateral sacral nerve stimulation is the most widely used method of testing for suitability 
for permanent sacral Neurostimulation implantation. It has been proposed that based on the 
bilateral innervations of the bladder, bilateral sacral nerve stimulation may improve the 
efficacy of this therapy. In a prospective randomized crossover trial comparing unilateral 
with bilateral stimulation using PNE screening, bilateral stimulation appeared to offer no 
definite advantage over unilateral stimulation. However, 2 of 13 patients voided only with 
bilateral stimulation and remained in retention with unilateral stimulation (Scheepens et al, 
2002).The authors concluded that bilateral test stimulation should be considered when 
unilateral stimulation fails. Further studies are needed to evaluate the role of bilateral 
stimulation during test stimulation trials, as well as during post implantation chronic phase. 
6.3 Implantation 
6.3.1 Position 
Buttock placement (figure 4D) of the IPG has an attractive alternative to the subcutaneous 
implantation in the lower part of the anterior abdominal wall because of  shorter operation 
time, avoidance of repositioning the patient during the operation and lower incidence of 
complications ( Scheepens et al, 2001) . 
6.3.2 Technique 
After successful test phase, the patient is brought to the OR for implantation of the 
permanent implantable pulse generator (IPG).If the first test was one stage, fluoroscopy is 
needed for permanent lead insertion. Broad spectrum preoperative antibiotics as Ampicillin 
and Gentamicin are given intravenously. (We usually perform 5 minutes scrubbing of the 
operative field with dilute Povidone-iodine in addition to prepping with chlorhexidine). The 
quadripolar tined lead is inserted in a similar fashion on the side where the patient had the 
best PNE test response. The lead is then tunneled in the subcutaneous fat to a pocket formed 
in the left or right buttock region according to the patient hand dominant site. It is attached 
to the connector & IPG which will be buried deep in the subcutaneous pocket. On the other 
hand, if the first phase was two- staged procedure the implantation is done as the 2nd stage, 
it does not require fluoroscopy, and can be done under local  or general anesthesia. The 
previous incision where the temporary connector was placed in the buttock is opened and 
the permanent IPG is connected to the lead after removal of the temporary connection 
system. A pocket is formed & irrigated with antibiotic mixed with sterile water to minimize 
infection risk. Then, the IPG is buried deep in the subcutaneous tissue in the buttock. Post 
operatively, the IPG is switched on and programming is done. 
 
Sterile water is used in irrigation and mixing with antibiotics, avoids electrical circuit 
formation & IPG erosion. 
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 Percutaneous Nerve 
Stimulation   (PNE) 
     Feasible PNE     Difficult PNE  
3-5days stimulation trial 
≥50% subjective 
and/or objective 
response 
SNM 
permanent 
implantation 
   No response
Staged procedure
14 days stimulation trial
No response, 
change electrode 
mapping 
If no response, 
Remove the 
quadripolar 
electrode, 
patient is not a 
candidate for 
SNM
≥50% 
response  
2
nd
 stage 
permanent 
IPG 
implantation 
Ask for vibration sensation at the 
target areas
Intact sensation
Remove the lead 
patient is not a 
candidate for SNM 
*Absent sensation 
*Sensation faded after time 
*Sensation not at target area 
Check electrode position on X-ray
Lead is not in position (lead migration) Lead In proper position
Repeat PNE or 
staged procedure 
Change electrode 
mapping on EPG 
No sensation
Positive sensation 
proceed to stimulation 
trial for 5 days
≥50% 
response 
proceed to 
SNM 
permanent 
implantation 
No response 
remove lead 
Remove lead, patient 
not candidate 
 
 
 
Fig. 2. Algorithm adapted by the Authors to minimize the false negative cases in Stimulation 
test trial 
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Fig. 3. A: Quadripolar tinned lead , the electrodes are shown, B: Sacral foramen needle is 
inserted  and guided to the desired location, C: Location is verified by electrical stimulation 
to the needle, and fluoroscopy is used to confirm the position of the needle in the S3 
foramen, D: The metal dilator is removed and plastic dilator is positioned, E: The 
quadripolar lead is introduced through the dilator plastic sheath into position which is 
confirmed by stimulation, the plastic dilator sheath in withdrawn carefully under 
fluoroscopic guidance Pictures adapted from Medtronic Inc, 2003. 
C
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Fig. 4. A: Fluoroscopic view of the sacral foramens, B: Permanent electrode leads position; 
note that the last electrode is located at the lower surface of the sacral canal, C: A-P view of 
the electrode position ,D: IPG position. Pictures adapted from Medtronic Inc, 2003. 
7. Complications 
The Sacral Nerve Stimulation study group has published several reports on the efficacy and 
safety of the procedure for individual indications. Siegel summarized the reported efficacy 
and complications in the total patient group who were included in the trials conducted by 
the neuromodulation study group. The complications where pooled from the different 
studies because the protocols, devices, efficacy results and safety profiles were identical. Of 
the 581 patients, 219 underwent implantation of the Interstim system (Medtronic, 
Minneapolis, Minnesota). 
The complications were divided into percutaneous test stimulation-related and post 
implantation related problems. Of 914 test stimulation procedures done on the 581 patients, 
181 adverse events occurred in 166 of these procedures (18.2% of the 914 procedures).Most 
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complications were related to lead migration (108 events, 11.8% of procedures). Technical 
problems and pain represented 2.6% and 2.1% of the adverse events. For the 219 patients 
who underwent implantation of the InterStim system (Lead and generator), pain at the 
neurostimulator site was the most commonly observed adverse effect at 12 months (15.3%) 
(Siegel et al, 2000) table 3. 
Cleveland Clinic reported complication rate in 160 patients who proceeded to permanent 
IPG implantation from total of 214 lead implants. 17 patients (10.5%) had device completely 
removed for infection and failure of clinical response.26 patients (16.1%) underwent device 
revision for attenuated response, infection, IPG site pain and lead migration. The majority of 
patients with revisions due to poor response had an abnormal impedance measurement. As 
a result, the author strongly advocate impedance measurement in patient evaluation in 
patients with response related dysfunction (Hijaz et al, 2006)  
 
PNE (one- stage) Tined lead (Two –stage)
Advantages: 
 In-office, under local anesthesia. 
 Greater patient acceptance( Minimal 
invasive) 
 Removal of leads in office , no need for 
experience 
 Accurate patient feedback during 
insertion (no interference from IV 
sedation) 
 Less costly, more favorable 
reimbursement. 
 Less risk of infection since permanent 
lead and IPG will be placed in one 
sitting after successful PNE. 
 
Advantages:
 Less risk of lead migration during the 
test trial. 
 Greater comfort due to level of 
sedation for anxious or pain focused 
patients. 
 Quadripolar lead configuration allows 
for more precise placement and 
programming. 
 Symptom improvement remains 
unchanged when converted to chronic 
implant. 
 Longer trial period to assess for 
symptom improvement 
 Higher rate of true positives. 
Disadvantages:
 Higher rate of false negatives. Must do 
staged implant if equivocal. 
 Potential to place permanent lead in 
less favorable location, thus requiring 
re-operation. 
 
Disadvantages:
 Requires two surgeries even if trial is 
unsuccessful 
 Greater potential for infection due to 
increased length of trial and potential 
contamination of permanent lead. 
 More expensive if trial is unsuccessful 
Table 2. Comparison of the advantages and disadvantages of one- stage (PNE) and two –
stage implant (with tined lead) (Elizabeth et al 2010) 
7.1 Lead migration 
Lead migration can be simply resolved by reprogramming, reinforcing the lead or insertion 
of a new lead contra-laterally (Deng et al, 2006) some patients lose benefit due to 
accommodation to the stimulation, but contralateral placement can be attempted to 
overcome this phenomenon (Wagg et al., 2007) 
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7.2 Infection 
When infection is diagnosed, the best management is explantation of the IPG, debridement 
of the infected tissue & antibiotics. The lead can be left behind but keeping in consideration 
that the infection may spread through it & if needed, may be removed. The wound is left to 
heal by secondary intention & the patient is covered with antibiotic for two weeks. Another 
IPG implantation can be considered after 6-8 weeks if inflammatory signs has resolved. 
Complication Probability of occurrence ( Siegel series) 
Pain at the Neurostimulation site 
New pain 
Suspected lead migration 
Infection 
Transient electric shock 
Pain at lead site 
Adverse change in bowel function 
Technical problems 
Suspected device problems 
Change in menestral cycle 
Adverse change in voiding function 
Persistent skin irritation 
Suspected nerve injury 
Device rejection 
15.3% 
9% 
8.4% 
6.1% 
5.5% 
5.4% 
3.0% 
1.7% 
1.6% 
1.0% 
0.6% 
0.5% 
0.5% 
0.5% 
Table 3. Reported complications with sacral neuromodulation therapy from the 
neuromodulation study group (Siegel et al, 2000) 
7.3 Impedance related complications 
Impedance describes the resistance to the flow of electrons through a circuit. Impedance or 
resistance is an integral part of any functioning circuit, but if there is too much resistance, no 
current will flow (Open). On the other hand, if there is too little resistance, an excessive 
current flow results in diminished battery longevity (Short). In the InterStim system, the 
circuit travels from the electrode through the patient tissue to another electrode (Bipolar) or 
through the patient tissue to the neurostimulator case (IPG) (Unipolar). 
Impedance measurement is used as a troubleshooting tool to check the integrity of the 
system when the patient present with sudden or gradual disappearance of stimulation. 
Usually the normal measurement falls between 400 and 1500 Ω. High levels (˃4000Ω) 
identify open circuit, usually is caused by fractured lead or extension wires, loose 
connections. In open circuits, the patient feels no stimulation. In these cases, the 
programmer which measures the impedance can be used to know which electrode is 
broken. Managing these cases can be done by reprogramming .The new mapping should 
avoid the broken electrode. If reprogramming is exhausted in these cases with no benefit, 
then revision is done. The aim of the revision is to identify the source of the open circuit (the 
electrode or connection). 
On the other hand, low levels (<50Ω) identify short circuits which can be caused by body 
fluid intrusion into the connectors or crushed wires that are touching each other. Patients 
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may not feel stimulation, or may feel it away from the correct area as the IPG pocket. Again, 
reprogramming followed by revision are the options in these cases.  
7.4 Pocket (IPG site) pain, discomfort  
IPG site pain is caused by either pocket –related, or output- related causes, see figure 5. To 
determine which is the case in the patient; turn the IPG off, if pain or discomfort persist, it 
means that the patient is having a pocket- related cause. Revision of the IPG and relocation 
can resolve the problem. 
If the pain disappears, that implies an output- related cause. In these cases, check the patient 
mapping. If the patient is having a monopolar one change it into a bipolar (some patients 
are sensitive to the unipolar because the positive pole is the IPG). Another possibility is 
current leak, try reprogramming (Mapping, Pulse width, and rate). If it did not show any 
benefit, ask the patient if that discomfort is tolerable (burning sensation usually at the 
pocket and perineum), if not revision is advocated 
 
Fig. 5. Causes of IPG site discomfort (Hijaz et al, 2005) 
7.5 Recurrent symptoms 
When the patient presents with recurrent symptoms, we need to evaluate the impedance, 
battery, and stimulation perception. The impedance abnormalities were discussed 
previously. If the battery was low with decreased sensation, this warrants new IPG (battery) 
exchange (Anecdotally, the battery mean half life we have encountered ranged between 7 to 
9 years, depending on the usage). The possibilities are that the patient perceives the 
stimulation in wrong area compared with the baseline, has no stimulation, or has 
intermittent stimulation, see management algorithm at figure 6 
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8. Contraindications for patients with implanted IPG  
Contraindications for patients with implanted IPG include short wave diathermy, 
microwave diathermy or therapeutic ultrasound diathermy (Medtronic professional use 
manual, 2011). MRI & pregnancy are special conditions at which implanted Neurostimulation 
is contraindicated 
8.1 Diathermy 
The diathermy’s energy anywhere in the body can be transferred through the implanted 
system and can cause tissue damage which could result in severe injury or death. Diathermy 
can also damage parts of the Interstim therapy system. This can result in loss of therapy 
from the Neurostimulation, and can require additional surgery to remove or place parts of 
the Interstim therapy system. 
 
Fig. 6. Management algorithm for different stimulation perception (Hijaz et al, 2005). 
8.2 Neuromodulation and MRI 
MRI is a safe, non invasive and essential diagnostic tool. Currently the number of patients 
who have bladder Neurostimulation is growing rapidly. For many reasons, their conditions 
often need magnetic resonance (MRI) examination. However the current practice is to 
contraindicate patients with implantable devices (Shellock and Kanal, 1992) (Achenbach et 
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al, 1997).Medtronic product technical manual indicates that exposure to MRI can potentially 
injure the patient or damage the Neurostimulator (Medtronic professional use manual, 
2011). The induced electrical current from the MRI to the Interstim therapy system can cause 
heating, especially at the lead electrode site, resulting in tissue damage. The induced 
electrical current can also stimulate or shock the patient. The precaution is applied even if 
only a lead or an extension is implanted; it does not only apply to the IPG alone. Few factors 
increase the risk of heating and injury, but are not limited to, as high MRI Specific 
Absorption Rate (SAR) Radio Frequency (RF) power levels, MRI transmit coil that is near or 
extends over the implanted lead, implanted leads with small surface area electrodes, and 
short distance between lead electrodes and tissue that is sensitive to heat (Medtronic 
professional use manual). An MRI may permanently damage the neurostimulator, requiring 
to be removed or replaced .It also can reset the neurostimulator to power – on- reset values 
requiring reprogramming again. The Neurostimulation can move within the implanted 
pocket and align with the MRI field, resulting in discomfort or reopening of a recent 
implanted incision. In addition, the image details from MRI may be degraded, destroyed or 
blocked from view by the implanted Interstim system( Shellock, 2001)(Ordidge et 
al,2000)(Luechinger et al,2002)(shellock et al,1993). In contrast, many studies conducted on 
patients who underwent MRI examinations with implantable devices showed no clinical 
adverse effects (Luechinger et al, 2001) (Martin et al, 2004) (Gimbel et al 1996) (Buendia et al, 
2011). Other concerns are associated with heating of the electrodes. Achenbach et al reported 
that temperature increase occurred at the tip of the pacing electrode (Achenbach et 
al,1997).However, Rezai et al reported that temperature elevations at the distal end of deep 
brain stimulation electrode of 25.3C occurred after 15 minute of MRI and noted that the use 
of clinically relevant positioning techniques for the Neurostimulation system and MRI 
parameters used for imaging the brain generated little heating ( Rezai et 
al,2002).Furthermore, Martin et al reported in 2004 that they found no evidence that increase 
in SAR increase the likelihood that the pacemaker lead would heat and cause subsequent 
threshold changes (Martin et al, 2004). In the case of sacral nerve Neurostimulator, a variety 
of symptoms could develop if the lead is heated (e.g. urgency with pelvic pain, urinary 
frequency, incontinence for stool or urine and possible sexual dysfunction in both men and 
women). Furthermore, Sommer et al have showed a significant decrease in temperature in 
leads of the pacemaker when the center of the region to be imaged was located 30 cm or 
farther from the center of the lead loop (Sommer, 2000).  
Nevertheless, Elkelini and Hassouna reported six patients with implanted sacral nerve 
stimulation who underwent eight MRI examinations at 1.0Tesla conducted in areas outside 
the pelvis (Elkelini and Hassouna, 2006). They examined the IPGs before and after the MRI 
procedure. All patients had their parameters recorded; then the IPGs were put to “nominal” 
status. Patients were monitored continuously during and after the procedure. During the 
MRI session, no patient showed symptoms that required stopping the examination. There 
was no change in the perception of the stimulation after reprogramming of the implanted 
sacral nerve stimulator, according to patients; feedback. Devices were functioning properly, 
and no change in bladder functions was reported after MRI examinations. 
8.2.1 Concluding message 
A lot of controversial issues arise in MRI safety in Neurostimulation implanted patients. 
There are no clear safety guidelines established yet. However, if a patient needs MRI it 
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would be preferred to postpone the Neurostimulation implantation till patient is done with 
it. Patients should be instructed about the potential injury of MRI, and to stop the MRI if 
they fell any heat at the IPG site. Those who will undergo MRI should have their IPG 
explanted. If the patient is having the electrode left behind or part of the electrode (ghost 
effect) it can act as an antenna and result into the heat injury to the nerve, when so the MRI 
procedure should be stopped. 
8.3 Neuromodulation and pregnancy 
Sacral nerve stimulation has been increasingly used in females of child bearing age with 
various voiding dysfunctions. Nevertheless, electrical stimulation has been considered a 
contraindication in pregnant women. Medtronic product technical manual indicates that 
safety and effectiveness have not been established for pregnancy, unborn fetus, and delivery 
(Medtronic professional use manual,2011). Although no firm evidence exists, concerns 
pertaining to neuromodulation during pregnancy include negative effects on the fetus, 
conceiving mother, and the InterStim device itself as shown in table 4. Few animal studies 
have attempted to address this issue. In addition, data on human subjects is scarce and 
available in the form of case reports and small cases series.  
8.3.1 Animal data 
Wang and Hassouna were first to examine the effect of electrical stimulation on pregnant 
rats and fetuses (Wang and Hassouna, 1999). The authors divided 20 Sprague-Dawley 
pregnant rats into either electrical stimulation group (n = 10) or sham controls (n = 10). Rats 
in the stimulation group were stimulated 7 hours every day from Day 4 to Day 20 of 
gestation. Stimulation was done bilaterally at the level of S1, bipolar of 3 volts and frequency 
20 Hz. The stimulation was adjusted to 80% of the value that induced a visible tail tremor. 
All pregnant rats were sacrificed and fetuses were examined at near term (Day 20 of 
gestation). The results showed that all pregnant rats were healthy during the gestation 
period and no abortions were observed. There was no significant difference between the 
stimulation group (2.27 +/- 0.51 gm.) and the sham group (2.13 +/- 0.51 gm.; p = 0.91) in 
terms of fetal body weight.  
 
Fetus Conceiving mother InterStim device 
 Teratogenicity  
 Fetal malformation 
 Abortion 
 Premature labour 
 Irritation and ulceration of 
the stretched skin over the 
battery (depending on the 
site of the battery) 
 Obstetric and anaesthetic 
care difficulties / 
complications 
 Pain at the lead site 
 Lead migration 
 Battery failure 
 Stretching the lead 
extender by the 
expanding abdomen 
Table 4. Neuromodulation potential concerns during pregnancy (Wiseman et al, 2002) 
(Gaynor et al, 2006) (Nartowicz et al 1980),(Smimova et al, 1982) (Bernardini et al ,2010) 
(Saxena et al, 2009)  
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No significant difference was seen in the number of resorptions between both groups. All 
fetuses were alive at the time of caesarean section. No fetal malformation was observed in 
gross appearance, viscera and skeleton of all rats. 
Karsdon at al. carried out an experiment to examine if uterine contractility during 
parturition can be inhibited with an electrical current (Karsdon et al, 2006). Electrical 
inhibition of in vitro spontaneously contracting preterm or term gestational rat 
myometrium tissue and in vivo spontaneously contracting uterus either directly in the 
rabbit and rat or transvaginally in the rat was studied. There was a decreased rat in vitro 
myometrial tension by 50%, decreased in vivo rabbit intrauterine pressure by 48%, 
decreased in vivo rat intrauterine pressure by 80%, and increased birth intervals (latency) 
by factors of 50 and 20. In addition, all electromyographic activity parameters were 
reduced significantly. The authors suggested that electrical inhibition may be a novel 
method to apply tocolysis in the human. These results, of course, argue against the 
concern premature labour induced by neuromodulation. In the same vein, Fujii et al. 
found that applying sacral surface electrical stimulation (ssES) treatment markedly 
decreased the peak power of uterine peristalses in comparison with that measured before 
ssES on the day of embryo transfer (ET)(Fujii et al,2008). Since the uterus at the time of ET 
is sensitive to ssES, the investigators speculated that electrical neuromodulation may be 
an effective method to induce uterine relaxation for ET. 
8.3.2 Human data 
Published data on human subjects is limited. It involves case reports and series of pregnant 
women undergoing a form of neuromodulation either for bladder or non-bladder related 
reasons. Saxena and Eljamel described 1 case report of young woman who had Spinal cord 
stimulation (SCS) implanted for chronic pain and then became pregnant (Saxena et al, 2009). 
In this case, the epidural SCS was high in the thoracic region with the epidural lead placed 
at T6 level. The IPG was implanted in the anterior abdominal wall being secured in a 
subcutaneous pocket. The patient had normal course of pregnancy and fetus development 
while the stimulation was on. However, she developed new severe pain at the side of the 
abdomen at the junction between the epidural lead and the lead extender, which became 
intolerable in the 25th week of gestation. Eventually, the lead extender wire was surgically 
cut in the 28th week of gestation under local anaesthesia. The rest of the pregnancy was 
uneventful. The authors suggested that if the IPG was implanted in a location that was 
unlikely to be affected by the enlarging gravid abdomen or if the lead extender was long 
enough, then she would have managed to continue her pregnancy without this mechanical 
related pain. Bernardini et al. also reported two female patients with complex regional pain 
syndrome I who were well managed with SCS and then became pregnant (Bernardini et al, 
2010). In both cases, the leads were placed through the T12/L1 inter-space and the IPG was 
placed in the buttock region. In the first patient, the device was kept deactivated prior to 
pregnancy and maintained off for the entire duration of the pregnancy. The second patient 
became pregnant on two separate occasions, with active SCS for a portion of the first 
trimester (8 weeks) of her first pregnancy before turning it off. She went on to deliver a 
healthy full-term neonate via caesarean section under general anaesthesia. During her 
second pregnancy, she deactivated the device 5 weeks post conception, however the patient 
elected to use SCS at 30 weeks' gestation because the pain became intolerable. There were no 
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obstetric or anaesthetic care complications related to the physical presence of the device. 
Rechargeable SCS systems were not affected when turned off during the duration of the 
pregnancy in both cases. In addition, intrauterine exposure to SCS was followed out for a 
minimum of two years and the developing fetuses were developmentally normal. Further 
reviewing of the literature also found two older case reports of SCS in the cervical spine to 
manage complex regional pain syndrome with concomitant usage during pregnancy to 
avoid the utilization of potentially teratogenic painkillers. In the first patient, there was a 
full term safe vaginal delivery despite the stimulator being switched on throughout 
pregnancy, labour, and delivery (Segal, 1999). In the second patient, she had SCS in the 
cervical spine 30 months before the pregnancy and had normal delivery under epidural 
anesthesia with no effects on the fetus or mother (Hanson and Goodman, 2006). One note 
regarding these patients is that the IPG was implanted in the subclavicular fossa. In 1988, 
Nanninga et al. reported the first case of the effect of sacral nerve stimulation for bladder 
control during pregnancy in a patient with myelodysplasia (Nanning et al, 1988). The 
patient activated the device to inhibit the bladder and deactivated it to allow voiding. Its use 
during pregnancy did not seem to have any adverse effect. In another report, a 30-year-old 
woman diagnosed with interstitial cystitis received a paddle lead (two lamitrode 44 paddles 
were placed in the sacrum such that they overlay at S2, S3, and S4 roots). The patient 
became pregnant but never used her stimulator during pregnancy (Feler et al, 2003). When 
Dasgupta et al. reviewed the long-term results of sacral nerve stimulation in the treatment of 
women with Fowler’s syndrome over a 6-year period at one referral center, they found that 
there were 20 patients still voiding spontaneously at the time of review (with two having 
deactivated their stimulator because of pregnancy) (Dasgupta et al, 2004). There was no 
further elaboration regarding outcomes during or after pregnancy.  
Sutherland et al. reviewed their 11 years experience with SNS for the management of 
refractory voiding dysfunction (Sutherland et al, 2007). Two patients in this cohort became 
pregnant after successful initiation of SNS therapy. One patient was treated for urgency and 
frequency 2 years prior to pregnancy. Pregnancy was carefully planned and neuromodulation 
was gradually decreased until it was deactivated. Nevertheless, her symptoms remained 
controlled during pregnancy. Following a successful vaginal delivery of a full-term baby, a 
temporary period of lead reactivation was needed due to postpartum idiopathic urinary 
retention and pain. Thereafter, the patient was free of symptoms, and remained so without 
neuromodulation. In the second patient, the same satisfactory efficacy was never obtained 
following postpartum device reactivation, and the device was eventually explanted. Lead 
migration during pregnancy and/or vaginal delivery was assumed to be the cause of 
decreased effectiveness, but this assumption was never confirmed radiographically.  
Siegel presented an abstract regarding an internet-based survey of InterStim implanters 
pertaining to their views and approaches to neuromodulation in pregnant patients (Siegal, 
2009). The survey showed that 66% of implanters have implanted a device in a woman 
younger than 30 years old. In patients that became pregnant, 2/3 decided to deactivate 
during the first trimester. Thirty-eight percent had patients with active devices during 
pregnancy, and 19% noted a change in efficacy after delivery. The survey concluded that 
there is likely little morbidity from having an active neuromodulation during pregnancy, 
however most implanters choose to deactivate on discovery of pregnancy. Perhaps the 
largest and most cited case series pertaining to SNS and pregnancy was published by 
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Wiseman et al. in 2002 (Wiseman et al, 2002). The authors obtained data on 6 women on SNS 
who then achieved pregnancy. The information was gathered using a standard 
questionnaire from 4 physicians known to treat patients on sacral neuromodulation. Data on 
indication for SNS, pregnancy course, the mode of delivery, neonatal health, the timing of 
implant deactivation and reactivation were all recorded. The results showed that in 1 
patient, stimulation was switched off 2 weeks before conception and was never reactivated 
in the post partum period. In 5 patients the stimulator was deactivated between weeks 3 and 
9 of gestation, after which 2 with a history of urinary retention had urinary tract infection, in 
which one of them also had IPG site pain and developed premature delivery at 34/40 
weeks. Normal vaginal delivery was observed is 3 patients, including 1 in whom 
subsequent implant reactivation did not resolve voiding dysfunction. Elective caesarean 
section was carried out in the other 3 cases; in which 1 with urinary retention had to have 
the device switched back on at 19/40 weeks due to difficult catheterization without any 
complications during pregnancy. All neonates in the series were healthy. Based on their 
small cohort, the authors suggested few recommendations: 1) the device should be 
deactivated if a patient on neuromodulation becomes pregnant, 2) reactivation should be 
considered when deactivation leads to urinary related complications that threaten the 
pregnancy, 3) elective caesarean section should be discussed with the patient since it is 
possible for sacral lead damage or displacement to occur during vaginal delivery. Finally, 
Govaert et al. described a pilot study to assess the influence of SNS on endometrial waves of 
the non-pregnant uterus by using diagnostic ultrasound to study various aspects of uterine 
activity (Govaert et al, 2010). Six patients with an implanted SNS for faecal incontinence 
were included (3 premenopausal and 3 postmenopausal). Ultrasound recordings were 
performed with the stimulator turned off and in three stimulation frequencies. All 
premenopausal patients showed some form of endometrial activity when the stimulator was 
turned off. This activity was maintained when the stimulator was turned on in two patients, 
but disappeared in one patient. On the other hand, all postmenopausal patients had no 
endometrial activity with the stimulator turned off. Only one postmenopausal woman 
showed endometrial activity when the pacemaker was set at a frequency of 21Hz. The 
investigators concluded that in premenopausal women SNS seems to exhibit no effect or an 
inhibitory effect rather than an excitatory effect on uterine activity. Nevertheless, they were 
unable to recommend any guidelines for SNS usage during conception and pregnancy. 
8.3.3 Concluding message 
Not much is known about the effects of SNS on uterocervical function, pregnancy, and the 
developing fetus. Few studies on pregnant animals do not suggest any issues, but data on 
pregnant and non-pregnant women is scarce precluding the issuing of any firm 
recommendations or guidelines. Therefore, until such clear evidence exists, it is advised to 
turn off the stimulator during pregnancy or to wait with permanent implantation of the 
device until after family completion has been achieved. 
9. Summary 
Sacral neuromodulation offers minimally invasive treatment for voiding dysfunction. 
Despite many advances in the techniques of neuromodulation, the mechanism of 
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neuromodulation remains undefined. Many technical challenges raised with the widespread 
use of this new therapy. Special attention is given for pregnant patients. Precautions should 
be followed to avoid complications in both pregnancy & MRI procedures in sacral 
neuromodulation patients. 
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